Denis Dupoiron
Denis Dupoiron
Cancer pain management is a major challenge in both Europe and the United States. Recent studies show that the incidence of cancer pain remains high and even increases at an advanced stage of the disease. ...
Purvi Patel
Purvi Patel
When discussing cancer treatment, it is important to be aware of the potential toxicities and side effects associated with these treatments. © 2021. Spr...
Cancer Pain Syndromes [0.03%]
癌症疼痛综合症
David Y Lee,John J Lee,Steven H Richeimer
David Y Lee
Pain from cancer can present in a multitude of ways. In this chapter, we will identify the types of cancer pain and their etiologies. Following this, we will explore how cancer pain can present as somatic pain, visceral pain, and neuropathi...
David J Copenhaver,Ming Huang,Jasmine Singh et al.
David J Copenhaver et al.
Pain is indelibly associated with the cancer experience. A systematic review and meta-analysis indicate that the prevalence of cancer pain is 55% during anticancer treatment, 66.4% in advanced, metastatic, or terminal disease, and 39.3% aft...
Lawrence A Stern,Vanessa D Jonsson,Saul J Priceman
Lawrence A Stern
The past two decades have marked the beginning of an unprecedented success story for cancer therapy through redirecting antitumor immunity [1]. While the mechanisms that control the initial and ongoing immune responses against tumors remain...
Immunogenic Cell Death Driven by Radiation-Impact on the Tumor Microenvironment [0.03%]
辐射诱导的免疫原性细胞死亡及其对肿瘤微环境的影响
Takahiro Yamazaki,Claire Vanpouille-Box,Sandra Demaria et al.
Takahiro Yamazaki et al.
Immunogenic cell death (ICD) is a particular form of cell death that can initiate adaptive immunity against antigens expressed by dying cells in the absence of exogenous adjuvants. This implies that cells undergoing ICD not only express ant...
Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors [0.03%]
实体瘤免疫检查点抑制剂抗性克服的转化生物标志物和理性策略
Justin A Chen,Weijie Ma,Jianda Yuan et al.
Justin A Chen et al.
Immune checkpoint inhibitors (ICIs) targeting the programed cell-death protein 1 (PD-1) or its ligand PD-L1 and cytotoxic T-lymphocyte antigen 4 (CTLA-4) pathways have improved the survival for patients with solid tumors. Unfortunately, dur...
Eleonora Timperi,Elena Vissio,Caterina Marchiò et al.
Eleonora Timperi et al.
In this chapter, we summarize the latest findings in the field of immuno-oncology of women cancers, particularly ovarian and breast tumors. We describe the relationship between immune parameters and clinical outcomes by evaluating the contr...
The Role of the Immune Infiltrate in Distinct Cancer Types and Its Clinical Implications : Lymphocytic Infiltration in Colorectal Cancer [0.03%]
肿瘤免疫微环境的多样性及其临床意义：结直肠癌中的淋巴细胞浸润
Jérôme Galon,Daniela Bruni
Jérôme Galon
Colorectal cancer (CRC) represents a major public health challenges, with one of the highest incidences worldwide. The two affected anatomical sites in CRC, i.e. the colon and the rectum, share important underlying features, but often diffe...
Sara I Pai,Alessandra Cesano,Francesco M Marincola
Sara I Pai
Checkpoint inhibitor therapy (CIT) has revolutionized cancer treatment but it has also reached a standstill when an absent dialog between cancer and immune cells makes it irrelevant. This occurs with high prevalence in the context of "immun...